Key result
Between 1990 and 2017, the age-standardized disability-adjusted life years (DALY) rate for hypertensive heart disease in Iran increased by 51.6% for men and 4.4% for women.
Why the study?
Hypertension and hypertensive heart disease (HHD) are major health concerns that reduce quality of life, prompting an assessment of the burden of HHD in Iran compared with World Bank upper middle-income countries and globally.
Observational
The burden of hypertensive heart disease in Iran has significantly increased from 1990 to 2017 and is substantially higher than global and upper middle-income country averages.
BACKGROUND: Hypertension and its consequent end-organ damage including Hypertensive Heart Disease (HHD) are a major concern that impact health, resulting into impairment and reduced quality of life (QOL). The purpose of this study was to describe the burden of HHD in Iran and comparing it with the World Bank upper middle-income countries (UMICs) in terms of disability-adjusted life years (DALY), mortality and prevalence. METHODS: Using data from the Global Burden of Disease study 2017, we compared the number of DALYs, deaths and prevalence trends for HHD from 1990 to 2017 in all age groups for both sex in Iran, and compared the epidemiology and trends with UMICs and globally. RESULTS: The age-standardized DALY rate for HHD increased by 51.6% for men (95% uncertainty interval [UI] 305.8 to 436.7 per 100,000) and 4.4% for women (95% UI 429.4 to 448.7 per 100,000) in Iran. The age-standardized prevalence of HHD in Iran was almost twice times higher than globally and 1.5-times more than the World Bank UMICs. The age-standardized death rate for HDD increased by 60.1% (95% UI 17.3 to 27.7% per 100,000) for men and by 21.7% (95% UI 25.85 to 31.48 per 100,000) for women from 1990 to 2017. Age-standardized death rate in Iran was 2.4 and 1.9 times higher than globally and UMICs, respectively. CONCLUSIONS: The higher prevalence and death rate in Iran in comparison with UMICs and globally should encourage health care provider to perform intensive screening activities in at risk population to prevent HHD and mitigate its mortality.
No takes yet. Share an insight, caveat, or question.
Omidi et al. (2021) conducted an observational in Hypertensive Heart Disease. Time period (2017 vs 1990) vs. 1990 baseline was evaluated on Age-standardized DALY rate for HHD. Between 1990 and 2017, the age-standardized disability-adjusted life years (DALY) rate for hypertensive heart disease in Iran increased by 51.6% for men and 4.4% for women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: